Jiangsu Hengrui Medicine Co., Ltd

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1970-01-01

Employees: -

Market Cap: $38.9B

Website: http://www.hrs.com.cn/english/

Clinical Trials

A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

Phase 3

Recruiting

Conditions: Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)

Interventions: Drug: HRS-8427
Drug: Imipenem and Cilastatin Sodium
Drug: Imipenem and Cilastatin Sodium placebo
Drug: HRS-8427 placebo

First Posted Date: 2024-08-23

Last Posted Date: 2024-10-10

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 578

Registration Number: NCT06569056

Locations: 🇨🇳
Shanghai Huashan Hospital, Shanghai, Shanghai, China

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

Phase 1

Not yet recruiting

Conditions: Advanced Unresectable or Metastatic Breast Cancer

Interventions: Drug: HRS-6209 in Combination with HRS-1358
Drug: HRS-6209 in Combination with Fulvestrant
Drug: HRS-6209 in Combination with Letrozole
Drug: HRS-6209 in Combination with HRS-8080

First Posted Date: 2024-08-15

Last Posted Date: 2024-08-15

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 528

Registration Number: NCT06555068

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery

Phase 2

Not yet recruiting

Conditions: Local Analgesia Via Nerve Block

Interventions: Drug: Bupivacaine Hydrochloride Injection
Drug: Bupivacaine Liposome Injection

First Posted Date: 2024-07-31

Last Posted Date: 2024-07-31

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 96

Registration Number: NCT06529432

Locations: 🇨🇳
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: HRS-4642

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-25

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 118

Registration Number: NCT06520488

Locations: 🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

SHR-4602 for Injection in Subjects With HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Phase 2

Not yet recruiting

Conditions: HER2-expressing or -Mutated Unresectable or Metastatic Solid Tumors

Interventions: Drug: SHR-4602

First Posted Date: 2024-07-24

Last Posted Date: 2024-07-24

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 240

Registration Number: NCT06516926

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Phase 3

Recruiting

Conditions: Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery

Interventions: Drug: Herombopag tablets
Drug: Herombopag placebo tablets

First Posted Date: 2024-07-18

Last Posted Date: 2024-08-14

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 101

Registration Number: NCT06507436

Locations: 🇨🇳
Zhongshan Hospital, affiliated with Fudan University, Shanghai, Shanghai, China

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Phase 3

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer With HER2- Mutations

Interventions: Drug: SHR-A1811
Drug: Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin

First Posted Date: 2024-05-28

Last Posted Date: 2024-05-28

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 300

Registration Number: NCT06430437

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Clinical Trial of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults

Phase 3

Not yet recruiting

Conditions: Gout With Hyperuricemia in Adults

Interventions: Drug: HR091506 tablets + placebo of febuxostat tablets
Drug: febuxostat tablets + placebo of HR091506 tablets

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 434

Registration Number: NCT06414837

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

Phase 2

Recruiting

Conditions: HER2 Expression / Amplification in Patients With Biliary Tract Cancer

Interventions: Drug: SHR-A1811

First Posted Date: 2024-05-14

Last Posted Date: 2024-07-08

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 65

Registration Number: NCT06413745

Locations: 🇨🇳
Zhongshan Hospital，Fudan University, Shanghai, Shanghai, China

A Study to Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Assisted Reproduction

Interventions: Drug: [14C]SHR7280

First Posted Date: 2024-05-10

Last Posted Date: 2024-07-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 6

Registration Number: NCT06408948

Locations: 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy